en Gynecology & Obstetrics Gynecology & Obstetrics Original Research Original Research The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of the sustained increase in haemoglobin neither the red ce1l2,3,-diphosphoglycerate (2,3- DPO) nor the P50 decreased from the pretreatment values. The mechanism which governs the rise in 2,3-diphosphoglycerate in chronic renal failure is different from the adaptive mechanism which operates in other types of anaemia. Recombinant Erythropoietin. Red Cell Metabolism, Chronic Renal Failure 229 231 http://mjiri.iums.ac.ir/browse.php?a_code=A-10-298-564&slc_lang=en&sid=1 MORTEZA AFRASIABI 20031947532846005992 20031947532846005992 Yes From the Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, The Coombe Hospital, Dublin ZAHRA ZOLNOORIAN 20031947532846005993 20031947532846005993 No From the Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, The Coombe Hospital, Dublin SEYYED HOSSEIN JAVADPOOR 20031947532846005994 20031947532846005994 No the Department of Renal Medicine, Adelide Hospital, Dublin 8, Republic of Ireland